Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

By Jeffrey L. Cummings, S. Isaacson, R. Mills, H. Williams, Kathy Chi-Burris, A. Corbett, Rohit Dhall, C. Ballard. The Lancet, 2014

612 citations recorded by the source corpus.

Subfields: Neurology

View Paper: https://www.semanticscholar.org/paper/7679b7560fb6c55a5bf16167b31e4882e79477af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Dennis W. Dickson
2. V. Lee
3. John Q. Trojanowski
4. E. Masliah
5. Daniel Weintraub
6. Andres M. Lozano
7. Eduardo Tolosa
8. A. Schapira

Citations in the corpus

• Past, Present, and Future of Parkinson’s Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy (2017, positive): “A new antipsychotic, pimavanserin (a selective 5HT2A inverse agonist) was recently approved in the United States specifically for PD psychosis.(59) All antipsychotics, including pimavanserin, carry a black box warning for increased mortality, a finding first reported in general dementia patients and”
• Diagnosis and management of dementia with Lewy bodies (2017, background): “Newer drugs targeting the serotonergic system, such as pi-mavanserin, 52 may be alternatives, but controlled clinical trial data in DLB are needed.”